Jennifer Eileen Van Eyk is the Erika Glazer Chair in Women's Heart Health, the Director of Advanced Clinical Biosystems Institute in the Department of Biomedical Sciences, the Director of Basic Science Research in the Women's Heart Center, a Professor in Medicine and in Biomedical Sciences at Cedars-Sinai.[1] She is a renowned scientist in the field of clinical proteomics.
Van Eyk began her academic career in 1996 as an assistant professor in the Department of Physiology at Queen's University, Kingston, Canada, and she was promoted to associate professor and received tenure in 2001.[3][5] She then left Canada to join Johns Hopkins University as the Director of the Proteomics Innovation Center in Heart Failure in 2003, and later Cedars-Sinai in 2014.[1][5][2]
Van Eyk is a member-at-large and a council member of Human Proteome Organization,[6] and the president of US Human Proteome Organization.[7] She was a technical briefs editor at Proteomics.[8] She served on the editorial board of Proteomics: clinical application and Journal of Physiology and Circulation Research.[9] She currently serves on the editorial board of Clinical Proteomics.[10] She is a Fellow of the International Society for Heart Research.[11] and is a Fellow of the American Heart Association.
Research
She is an international leading scientist in clinical proteomics.[12] She is the founding director of Cedars-Sinai Advanced Clinical Biosystems Research Institute,[13] whose motto is “from discovery to patient care”.[14]
She is co-editor of Clinical Proteomics: From Diagnosis to Therapy,[15] an essential, important and impressive book in clinical proteomics and translational medicine.[16]
2019 Human Proteome Organization Distinguished Achievement in Proteomic Sciences Award[23]
2019 US Human Proteome Organization The Donald F. Hunt Distinguished Contribution in Proteomics award[24]
2019 Canadian National Proteomics Network The Tony Pawson Proteomics Award[25]
2017 The Analytical Scientist Power List: Top 10 Omics Explorers[26]
2015 Human Proteome Organization Clinical & Translational Proteomics Award[27]
2014 American Heart Association Council on Genomic and Precision Medicine Medal of Honor[28]
2013 American Heart Association Council on Genomic and Precision Medicine Distinguished Achievement Award[29]
Recent Patents
Role of citrullination in diagnosing diseases (2021) US 11,105,817 B2[30]
Biomarkers of myocardial injury (2021) US 11,041,865 B2[31]
Correlated peptides for quantitative mass spectrometry (2019) US 10,352,942 B2[32]
Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease (2019) US 10,309,974 B2[33]
Diagnostic assay for Alzheimer's disease (2017) US 9,678,086 B2[34]
↑ USpatent 11,105,817B2,Jennifer Van Eyk, Justyna Fert-Bober, Erin Crowgey, Ronald Holewinski, Benjamin Phillip Berman,"Role of citrullination in diagnosing diseases",issued 2021-08-31
↑ USpatent 11,041,865B2,Qin Fu, Jennifer Eileen Van Eyk, Vidya Venkatrama,"Biomarkers of myocardial injury",issued 2021-06-22
↑ USpatent 10,352,942B2,Eric Grote, Qin Fu, Jennifer Van Eyk, Vidya Venkatrama,"Correlated peptides for quantitative mass spectrometry",issued 2019-07-16
↑ USpatent 10,309,974B2,Justyna P. Fert-Bober, Jennifer E. Van Eyk,"Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease",issued 2019-06-04
↑ USpatent 9,678,086B2,Jennifer Van Eyk, Xiaogian Liu, Richard O'Brien,"Diagnostic assay for Alzheimer's disease",issued 2017-06-13
This article needs additional or more specific categories. Please help out by adding categories to it so that it can be listed with similar articles.(November 2021)
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
